AuntMinnie.com staff writersImage-Guided SurgeryClearPoint reports spike in revenue in Q2ClearPoint Neuro posted double-digit growth in revenue in the second quarter of 2024, citing strong product sales.August 7, 2024Clinical NewsRSNA awarded $2M grant from NNSAThe RSNA has received a $2 million grant from the U.S. Department of Energy’s National Nuclear Security Administration (NNSA) to improve patient care in low- to middle-resourced countries.August 7, 2024Digital X-RayDocGo and MinXray launch TB initiative in New York CityMinXray, Inc.Mobile health services provider DocGo and portable digital x-ray developer MinXray have launched a program in New York City to help identify active tuberculosis (TB) cases in vulnerable populations.August 6, 2024Radiology EducationRSNA calls for entries for Art of Imaging contestRSNA said its popular Art of Imaging exhibit will take place in the Learning Center during the society’s annual meeting later this year and called for entries.August 6, 2024Molecular ImagingResearchers test dual PET/MRI imaging agent in miceA group in Germany has developed a new contrast agent that works with both PET and MRI.August 6, 2024Molecular ImagingPET tracer for cardiac amyloidosis gets FDA ‘breakthrough’ nodAttralus has received a breakthrough therapy designation from the U.S. FDA for its PET radiotracer iodine-124 (I-124) evuzamitide (AT-01).August 6, 2024CTBayer, Alara to collaborateBayer and Alara Imaging plan to collaborate on CT radiation dose software.August 5, 2024Industry NewsRoyal Philips to raise $137M in share repurchasePhilips parent company Royal Philips plans to repurchase 4.8 million shares to raise $137 million (125 million euros).August 5, 2024Radiation Oncology/TherapySirtex Medical introduces new Y-90 delivery methodRadiation oncology firm Sirtex Medical has introduced a new way to deliver yttrium-90 (Y-90) for metastatic colorectal cancer radiation therapy.August 5, 2024Molecular ImagingCereMark Pharma gets set for F-18 flornaptitril trialsCereMark Pharma is planning a phase III clinical trial to investigate the novel PET imaging agent F-18 flornaptitril.August 2, 2024Previous PagePage 106 of 192Next PageTop StoriesMolecular ImagingExperts issue appropriate use criteria for molecular breast imagingThe criteria offer use scenarios for technetium-99 (Tc-99m) sestamibi-based gamma camera imaging of the breast.MRIfMRI: Cognitive behavioral therapy positively affects the brainPractice ManagementPost Cures Act, outpatients access radiology reports fasterMRIMRI may help guide brachial plexus surgeryAIShould hospitals pursue local domain LLM adaptation for radiology reports?
![Current PET/MRI imaging of healthy and damaged mouse kidneys using the dual contrast agent F-18 [Gd (FL1)]. The imaging provides consistent signals from both PET and MRI. In healthy kidneys, the center of the kidneys appears dark in the MRI image and very bright in the PET image, indicating normal excretion of the contrast agent. The onset of impaired function in one kidney is indicated by the accumulation of the contrast agent and its slow excretion. Precise mapping of MRI and PET data ensures detailed morphological and quantitative analysis of kidney impairment. Image and caption courtesy of IOCB Prague.](https://img.auntminnie.com/files/base/smg/all/image/2024/08/PET_MRI_agent.66b25358df3b3.png?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
